Comparison of clinical effect of transcatheter arterial chemoembolization combined with microwave ablation and Apatinib Mesylate in treatment of intermediate and advanced primary liver cancer
DENG Zefeng
Department of Oncology, Jiujiang Third People′s Hospital, Jiangxi Province, Jiujiang 332000, China
Abstract：Objective To investigate the clinical effect of transcatheter arterial chemoembolization (TACE) combined with microwave ablation and Apatinib Mesylate in the treatment of intermediate and advanced primary liver cancer.Methods A total of 92 patients with primary liver cancer who were treated in the Department of Oncology of Jiujiang Third People′s Hospital from January 2018 to May 2019 were selected as subjects. They were divided into the microwave ablation group and the Apatinib Mesylate group according to random number table method, with 46 cases in each group. The microwave ablation group was given TACE combined with microwave ablation, and the Apatinib Mesylate group was given TACE combined with Apatinib Mesylate. The disease control rate (DCR), serum marker levels(serum alpha-fetoprotein [AFP], vascular endothelial growth factor [VEGF], matrix metalloproteinase-9 [MMP-9], cysteine aspartic proteinase-8 [caspase-8]), adverse events, and short-term survival rate were compared between the two groups. Results The DCR in the microwave ablation group was higher than that in the Apatinib Mesylate group, and the total incidence of adverse events in the microwave ablation group was lower than that in the Apatinib Mesylate group,with statistically significant differences (P<0.05). After treatment, the levels of serum AFP, VEGF and MMP-9 in the microwave ablation group were lower than those in the Apatinib Mesylate group, and the level of caspase-8 in the microwave ablation group was higher than that in the Apatinib Mesylate group, with statistically significant differences (P<0.05). There was no statistically significant difference in the one-year survival rate between the two groups (P>0.05).Conclusion TACE combined with Apatinib Mesylate or microwave ablation has a certain effect in the treatment of intermediate and advanced primary liver cancer. The two therapies have similar short-term survival rate, but TACE combined with microwave ablation has a better effect and the advantage of improving serum marker levels.
邓泽锋. 经导管动脉化疗栓塞分别联合微波消融与甲磺酸阿帕替尼治疗中晚期原发性肝癌的临床效果比较[J]. 中国当代医药, 2022, 29(8): 7-10.
DENG Zefeng. Comparison of clinical effect of transcatheter arterial chemoembolization combined with microwave ablation and Apatinib Mesylate in treatment of intermediate and advanced primary liver cancer. 中国当代医药, 2022, 29(8): 7-10.
Elsheikh AM，Teama MI，Afify AF，et al.Trans -arterial chemoembolization （TACE） in treatment of non-resectable hepatocellular carcinoma：comparative study between conventional TACE and drug eluting bead TACE[J].IJRPS，2020，11（3）：4733-4741.
[5]
Shimose S，Iwamoto H，Tanaka M，et al.Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma[J].Oncology，2020，98（8）：558-565.
[6]
Sonsuz A.Barcelona Clinic Liver Cancer（BCLC）Staging：Does It Cover All Our Expectation[J].J Gastrointest Cancer，2017，48（3）：260-261.
Jingyan W，Linzhi Z，Xiaoming P，et al.Combination of TACE and FOLFOX4 in the treatment of unresectable advanced hepatocellular carcinoma：a prospective cohort study[J].OTM，2020，6（5）：208-216.
京公网安备 11010502046607号